Canaccord Genuity analyst John Newman expects Bristol-Myers (NYSE: BMY) to acquire 100% control of bb2121 from bluebird bio (NASDAQ: BLUE) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE